🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Challenge

Cases of gonorrhoea are escalating globally, with data suggesting in excess of 82 million instances per year. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of growing infection rates, the spread of superbugs and the extremely scarce available drugs at this time.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This authorization represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Results and Global Access

According to findings detailed in a major medical journal, the new drug cured over nine in ten of uncomplicated infections. This puts it on an comparable level with the existing first-line therapy, which combines a dual-drug approach. The study involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians directly involved have shared optimism. Access to a single-dose, oral treatment such as this is seen as a "revolutionary step" for public health efforts. This is viewed as essential to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.